Biomea Fusion Announces Public Offering of Securities

SAN CARLOS, Calif., Sept. 22, 2026 /CourierPR/ -- Biomea Fusion, Inc., a clinical-stage diabetes and obesity company, has announced plans for a public offering of securities. The company intends to sell shares of its common stock and, in certain cases, pre-funded warrants to purchase shares of its common stock. Biomea Fusion is also granting the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock and pre-funded warrants in the proposed offering.

The proposed offering is subject to market and other conditions, and there is no guarantee that it will be completed or that the terms will remain as anticipated. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289262), filed with the U.S. Securities and Exchange Commission (SEC) on August 5, 2025, and declared effective on August 15, 2025. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and may be obtained from Konik Capital Partners, LLC, a division of T.R. Winston & Company.

Biomea Fusion is focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for the treatment of diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world's population. The company’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions.

The press release also includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements include Biomea’s beliefs and expectations regarding the proposed offering, uncertainties related to market conditions, and statements regarding the timing, size, and expected gross proceeds of the proposed offering. Biomea Fusion’s research, development, and regulatory plans, as well as the progress of ongoing and upcoming clinical trials, are also subject to these forward-looking statements.

Any forward-looking statements in the press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements. These risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Biomea’s most recent annual report on Form 10-K filed on March 24, 2026, and subsequent quarterly reports on Form 10-Q filed with the SEC.